EPHA2 and prostate carcinoma: The most active of these derivatives was the l-Trp derivative (88, PCM126) (Table 5), which, at low micromolar concentrations, significantly outperformed LCA in terms of breaking the EphA2–ephrinA1 connection and decreasing EphA2 phosphorylation in prostate cancer cells.